Webinar: The biomarker calprotectin - for plasma and serum
November 30, 2021 at 05:21 am EST
Share
Biomarker for early detection of the inflammatory response to infections
Calprotectin is one of the earliest biomarkers for detection of the inflammatory response to infections1,2. The biomarker is predominantly expressed in neutrophil granulocytes, and it is released upon neutrophil activation in response to inflammation and infection.
Calprotectin in plasma and serum can be a valuable biomarker in different areas:
discrimination between bacterial and viral infection3
assessment of severe infections and sepsis2,4,5
prediction for development of severe infections6
a risk marker in severe COVID-197,8
for non-infectious inflammatory diseases, like rheumatic diseases9
Watch webinar: The biomarker calprotectin to learn more
Get in touch for information and ordering
Interested in calprotectin for plasma and serum? Want to know more?Please send an email to marketing@gentian.comor fill out the form below:
References:
Fullerton J et al. Kinetics of calprotectin, procalcitonin and C-reactive protein in healthy volunteers administered intravenous endotoxin. 40th International Symposium on Intensive Care & Emergency Medicine. Critical Care. 2020. P474.
Jonsson N et al. Calprotectin as an early biomarker of bacterial infections in critically ill patients: an exploratory cohort assessment. Crit Care Resusc. 2017.
Havelka A et al. Calprotectin, a new biomarker for diagnosis of acute respiratory infections. Sci Rep. 2020.
Larsson A et al. Calprotectin is superior to procalcitonin as a sepsis marker and predictor of 30-day mortality in intensive care patients. Scand J Clin Lab Invest. 2020.
Simm M et al. Performance of plasma calprotectin as a biomarker of early sepsis: a pilot study. Biomark Med. 2016.
Parke Å et al. Plasma-calprotectin compared with routine biomarkers for prediction of early severe event in sepsis. 40th International Symposium on Intensive Care & Emergency Medicine. Critical Care. 2020.
Bauer W et al. Outcome prediction by serum calprotectin in patients with COVID-19 in the emergency department. J Infect. 2021.
Luis García de Guadiana Romualdo et al. Circulating levels of GDF-15 and calprotectin for prediction of in-hospital mortality in COVID-19 patients: A case series. J Infect. 2021.
Ometto F et al. Calprotectin in rheumatic diseases. Exp Biol Med (Maywood). 2017.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Gentian Diagnostics AS published this content on 30 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 November 2021 10:20:05 UTC.
Gentian Diagnostics ASA is a Norway-based company within health care sector. The Company develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Companyâs product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The Company is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.
GENTIAN DIAGNOSTICS 
